Social-ecological shifts, traps and collapses in small-scale fisheries: Envisioning a way forward to transformative changes

Small-scale fisheries (SSF) are critical to food systems and livelihoods. However, the relation between fisheries resilience, outcomes of proximate and distal drivers and the potential space for transformative changes have been largely unexplored. Such knowledge is key to understanding how fishery resources, institutions and actors respond to, and learn from, diverse drivers of change and social-ecological crises, as well as to design policies aimed at building resilience in SSF. This paper provides a new heuristic model to analyze the factors that combined lead SSF to trajectories towards shifts, traps and collapses, including the opportunity to navigate sustainable transformations. We illustrate the proposed Heuristic with three case studies with different biophysical and socio-cultural contexts and final outcomes: the Galician shellfisheries on foot (Spain), the Chilean king crab small-scale fishery (Chile), and the Galapagos sea cucumber small-scale fishery (Ecuador). The application of the Heuristic and a detailed description of model key elements for each case study provide practical examples and a valuable guide for fisheries scientists, practitioners and decision-makers to learn and/or respond in a flexible way to SSF social-ecological crises in the pursuit of fisheries sustainability and equity. Scholars are welcome to adopt our Heuristic to classify and bound SSF, order events, suggest hypotheses of linked drivers, pathways of change, potential trajectories, and outcomes, and envision potential space for transformative changes

Validation of an Engineered Cell Model for In Vitro and In Vivo HIF-1 alpha Evaluation by Different Imaging Modalities

n/

Applicazione ai Tissue Microarray delle tecniche di immunoistochimica e di Ibridazione In Situ Fluorescente per la caratterizzazione immunofenotipica e citogenetica di linfoma a grandi cellule B diffuso

Obbiettivo Lo scopo di questo lavoro \ue8 stato la costruzione di un Tissue Microarray (TMA) pilota per la valutazione immunofenotipica e citogenetica di una casistica di linfoma a grandi cellule B diffuso (DLBCL), tramite analisi immunoistochimiche e di Ibridazione In Situ Fluorescente (FISH). Materiali e Metodi Abbiamo costruito il TMA utilizzando le biopsie linfonodali di 12 pazienti affetti da linfoma a grandi cellule B diffuso; ne abbiamo ottimizzato la costruzione per la lettura al microscopio a fluorescenza distanziando in maniera differenziale i carotaggi dello stesso caso da quelli del casi adiacenti mentre per mantenere la rappresentabilit\ue0 tissutale abbiamo inserito cinque carotaggi da 2 mm per campione. Al TMA abbiamo applicato cinque protocolli immunoistochimici (CD10, BCL6, MUM1, GCET1 e FOXP1) e un protocollo FISH (cMYC). Risultati I dati immunoistochimici sono stati elaborati secondo gli algoritmi di Hans e Choi: secondo il protocollo di Hans sono risultati 8 DLBCL con profilo immunofenotipico centro germinativo simile (GCB) e 4 DLBCL con profilo attivato (ABC); in accordo con l'algoritmo di Choi 7 DLBCL GCB e 5 DLBCL ABC. La conformit\ue0 dei dati immunoistochimici ottenuti \ue8 stata valutata confrontando i risultati con quelli delle indagini immunoistochimiche eseguite su sezione interna, al momento della diagnosi. Abbiamo ottenuto in questo modo una concordanza del 100% con l\u2019algoritmo di Hans e una concordanza del 92% con l\u2019algoritmo di Choi. L\u2019analisi di MYC non ha evidenziato la presenza di traslocazioni ma in tre casi \ue8 stato possibile rilevare polisomie del cromosoma 8. Conclusioni Questo studio ci ha permesso di definire i criteri metodologici per la progettazione e la costruzione di un TMA (con una concordanza del 100% rispetto ai dati ottenuti al momento della diagnosi) che potesse essere letto agevolmente al microscopio a fluorescenza, fornendo cos\uec una piattaforma di analisi ad alta resa per l'esecuzione di indagini immunoistochimiche e citogenetiche FISH

Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report

Neutropenia in the setting of acute hematological malignancies may impact disease prognosis, thus affecting therapy dose intensity. This is often due to chemotherapy\u2011induced aplasia as well as to the disease itself. However, chronic neutropenia deserves further investigation, as the management of reversible concomitant causes may avoid treatment delay. The present study describes a case of an acute promyelocytic leukemia patient with chronic severe neutropenia of multifactorial origin, including acute leukemia itself, chemotherapy, autoimmune activation with anti\u2011platelets and anti\u2011neutrophil antibodies positivity, and the rare association of large granular lymphocyte (LGL) expansion. As neutropenia may challenge the diagnosis and treatment of acute malignancies, clinicians and hematopathologists must discuss the differential diagnosis in order to avoid misdiagnosing and undertreating concomitant diseases. In particular, LGL chronic expansion and autoimmunity should be considered

Reproducibility of the WHO histological criteria for the diagnosis of Philadelphia chromosome-negative myeloproliferative neoplasms.

This study, performed on behalf of the Italian Registry of Thrombocythaemias (Registro Italiano Trombocitemie), aimed to test the inter-observer reproducibility of the histological parameters proposed by the WHO classification for the diagnosis of the Philadelphia chromosome-negative myeloproliferative neoplasms. A series of 103 bone marrow biopsy samples of Philadelphia chromosome-negative myeloproliferative neoplasms consecutively collected in 2004 were classified according to the WHO criteria as follows: essential thrombocythaemia (n=34), primary myelofibrosis (n=44) and polycythaemia vera (n=25). Two independent groups of pathologists reviewed the bone marrow biopsies. The first group was asked to reach a collegial 'consensus' diagnosis. The second group reviewed individually all the cases to recognize the main morphological parameters indicated by the WHO classification and report their results in a database. They were subsequently instructed to individually build a 'personal' diagnosis of myeloproliferative neoplasms subtype just assembling the parameters collected in the database. Our results indicate that high levels of agreement ( 6570%) have been reached for about all of the morphological features. Moreover, among the 18 evaluated histological features, 11 resulted statistically more useful for the differential diagnosis among the different Philadelphia chromosome-negative myeloproliferative neoplasms. Finally, we found a high percentage of agreement (76%) between the 'personal' and 'consensus' diagnosis (Cohen's kappa statistic >0.40). In conclusion, our results support the use of the histological criteria proposed by the WHO classification for the Philadelphia chromosome-negative myeloproliferative neoplasms to ensure a more precise and early diagnosis for these patients

Erdheim-Chester Disease With Multiorgan Involvement, Following Polycythemia Vera : a Case Report

Erdheim-Chester disease is a rare form of non-Langerhans cell histiocytosis characterized by the migration and infiltration of lipid-laden CD68, CD1a and S100 histiocytes to various target organs, which leads to the disruption of physiological tissue architecture and reactive fibrosis, and thus impairs organ function.We describe the first case of a patient with Erdheim-Chester disease with multiorgan involvement developed after 6 years from polycythemia vera diagnosis. During the follow-up, an abdominal ultrasound scan revealed the presence of dense, bilateral perinephric infiltration. A computed tomographic guided core biopsy was performed in order to identify the histological nature of this lesion, and a morphological analysis demonstrated the accumulation of foamy histiocytes surrounded by fibrosis. The BRAFV600E mutation was detected, and a diagnosis of Erdheim-Chester disease was made.The extreme rarity of Erdheim-Chester disease strongly suggests the existence of potentially common element(s) that may have contributed to the pathogenesis of both disorders. Obviously, further studies are needed to clarify the mutual roles and effects of JAK2 and BRAF mutations in this patient, as well as their possible therapeutic implications

An unusual type of myeloid sarcoma localization following myelofibrosis : a case report and literature review

Myeloid Sarcoma (MS) is a rare malignancy that can present as an isolated disease or more frequently in association with or following acute myeloid leukemia or other myeloid neoplasms and rarely following myelofibrosis. Since molecular pathogenesis and prognostic factors of MS are not well understood, its prognosis remains poor even in the era of novel agents and target therapies. We report the case of a patient with MS following myelofibrosis with multiple subcutaneous, cutaneous and muscle localizations; the latter has been reported in the literature as anecdotal. In this way we aimed to enhance the understanding of this disease

Prognostic relevance of serum beta2 microglobulin in patients with follicular lymphoma treated with anthracycline-containing regimens. A GISL study.

Background and ObjectivesAlthough serum b2 microglobulin (b2M) is an easy parameter to measure, and overexpressedin a large number of lymphoproliferative diseases, its prognostic value hasbeen largely underestimated. The present study examined the influence of b2M levelson overall survival (OS) of patients with follicular lymphoma (FL).Design and MethodsThe prognostic role of b2M was evaluated in 236 patients with FL identified from thedatabases of the Gruppo Italiano per lo Studio dei Linfomi (GISL) and treated withanthracycline-based regimens from 1993 to 2003.ResultsElevated serum b2M levels were found in 82 patients (35%). According to multivariatelogistic regression analysis, elevated b2M levels were associated with elevatedlactate dehydrogenase (LDH) (p=0.021), age (p=0.029), and number of involvednodal areas (p<0.001). The percentage of elevated b2M levels increased progressivelywith increasing FLIPI scores (17%, 38%, and 63% in the low-, intermediate-, andhigh-risk groups, respectively). Five-year OS was 61% (95% CI, 47-73%) and 89% (95%CI, 82-93%) for patients with elevated vs normal b2M levels respectively (p<0.001).Cox regression analysis showed that b2M level had an independent and stable prognosticvalue (HR=3.0; 95%CI, 1.6-5.7). In a multivariate analysis the impact of b2Mlevel on survival was independent of FLIPI score, with a HR of 2.94 (95% CI, 1.54-5.62).Interpretation and ConclusionsOur results demonstrate that in patients treated in the pre-rituximab era, b2M levelwas an independent prognostic marker in addition to FLIPI score. We thus suggestthat b2M be routinely assessed and tested in future prognostic studies of FL patientstreated with combination chemotherapy and anti-CD20 agents

Acute myeloid leukemia and pregnancy: Clinical experience from a single center and a review of the literature

Background: Acute myeloid leukemia (AML) accounts for more than two thirds of leukemia during pregnancy and has an incidence of 1 in 75,000 to 100,000. Its clinical management remains a challenging therapeutic task both for patient and medical team, given to the therapy-attributable risks for mother and fetus and the connected counseling regarding pregnancy continuation. Methods: We provided a review of updated literature and a comprehensive description of five maternal/fetal outcomes of AML cases diagnosed concomitantly to pregnancy and treated at our Institution from 2006 to 2012. Results: Median age at AML diagnosis was 32 years (31-39). One diagnosis was performed in first trimester and the patient asked for therapeutic abortion before starting chemotherapy. Three cases were diagnosed in second/third trimester; in one case leukemia was diagnosed concomitantly with intrauterine fetal death, while the remaining two patients continued pregnancy and delivered a healthy baby by cesarean section. In only one of these two cases chemotherapy was performed during pregnancy (at 24 + 5 weeks) and consisted of a combination of daunorubicine and cytarabine. Therapy was well tolerated and daily fetus monitoring was performed. After completion of 30 weeks of gestation a cesarean section was carried out; the newborn had an Apgar score of 5/1'-7/5'-9/10', oxygen therapy was temporarily given and peripheral counts displayed transient mild leukopenia. One patient had diagnosis of myelodysplastic syndrome rapidly progressed to AML after delivery. Four out of the 5 described women are currently alive and disease-free. Three children were born and long-term follow-up has shown normal growth and development. Conclusions: The treatment of AML occurring during pregnancy is challenging and therapeutic decisions should be taken individually for each patient. Consideration must be given both to the immediate health of mother and fetus and to long-term infant health. Our series confirmed the literature data: fetal toxicity of cytostatic therapy clusters during the first trimester; while chemotherapy can be administered safely during second/third trimester and combination of daunorubicin and cytarabine is recommended for induction